etiological and clinical classification of pulmonary hypertension in children

Original title: “[Etiological and clinical classification of pulmonary hypertension in children].”

beyond heritable pah pulmonary hypertension in genetic syndromes

Original title: “Beyond Heritable PAH: Pulmonary Hypertension in Genetic Syndromes.”

08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with ... 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. About the PHrontier Study The Phase 3 PHrontier clinical study is a randomized (1:1), double-blind, placebo-controlled, global trial evaluating the safety and efficacy of mosliciguat in adult patients with PH-ILD. The study is currently designed to enroll approximately 375 patients worldwide. About Pulmonary Hypertension and Interstitial Lung Disease Pulmonary hypertension (PH) is a progressive and debilitating condition characterized by high blood pressure in the blood vessels of the lungs. It is a terrific example of the Roivant model working as planned: finding high-potential molecules and going after diseases where the patient needs are enormous and where the drug can truly shine.” · “Our robust Phase 2 PHocus study results, in conjunction with mosliciguat’s inhaled, once-a-day administration and potential first-in-class sGC activator profile, strongly position it as a potential single agent treatment and combination therapy for patients with PH-ILD.

Original title: “Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study - BioSpace”

pulmonary veno occlusive disease presenting as congenital heart disease associated pulmonary hypertension

Original title: “Pulmonary Veno-Occlusive Disease Presenting as Congenital Heart Disease-Associated Pulmonary Hypertension.”

diagnostic performance of the main pulmonary artery to ascending aorta diameter ratio for pulmonary hypertension defined by mean pulmonary arterial pressure in children with left to right shunt congenital heart disease

Original title: “Diagnostic performance of the main pulmonary artery-to-ascending aorta diameter ratio for pulmonary hypertension defined by mean pulmonary arterial pressure in children with left-to-right shunt congenital heart disease.”

pseudo infarction reversal in right precordial leads ecg evolution in severe pulmonary hypertension

Original title: “Pseudo-Infarction Reversal in Right Precordial Leads: ECG Evolution in Severe Pulmonary Hypertension.”

misdiagnosed as idiopathic pah methylmalonic acidemia as a reversible cause of pediatric pulmonary hypertension

Original title: “Misdiagnosed as Idiopathic PAH: Methylmalonic Acidemia as a Reversible Cause of Pediatric Pulmonary Hypertension.”

atrial flutter ablation in pulmonary hypertension a national referral center experience

Original title: “Atrial flutter ablation in pulmonary hypertension: a national referral center experience.”

case of chronic thromboembolic pulmonary hypertension and pregnancy managed with pulmonary endarterectomy clinical challenges case report and literature review

Original title: “A Case of Chronic Thromboembolic Pulmonary Hypertension and Pregnancy, Managed With Pulmonary Endarterectomy: Clinical Challenges, Case Report, and Literature Review.”

isolated absence of the right pulmonary artery a rare cause of pulmonary hypertension in adults

Original title: “Isolated Absence of the Right Pulmonary Artery: A Rare Cause of Pulmonary Hypertension in Adults.”

David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One / cancer, David Ross, IPF, Karen Yada Ross, Lung cancer, Natera, Karen continues to advocate for rare diseases such as PH-ILD with a sense of dedication, humility, and compassion. As part of the Pulmovant team, she aspires to make a meaningful difference for these courageous patients.”

Original title: “David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One - OncoDaily”

genetic variants in pulmonary hypertension associated with chronic obstructive pulmonary disease

Original title: “Genetic variants in pulmonary hypertension associated with chronic obstructive pulmonary disease.”

mutations in vcp cause adams oliver syndrome with or without pulmonary hypertension

Original title: “Mutations in VCP cause Adams-Oliver syndrome with or without pulmonary hypertension.”

For years, I knew something wasn’t right. I was experiencing symptoms that affected my daily life—shortness of breath, fatigue, and physical limitations that didn’t make… Continue reading The Diagnosis They Missed: A Journey from Dismissal to Advocacy I speak about the gaps that exist between patients and healthcare systems. I share the emotional and mental toll of living with chronic illness—the part that often goes unseen. And I work to help healthcare providers and organizations better understand what it truly means to live with a rare condition. My hope is that by sharing my story, others will feel less alone—and that those in positions to make change will listen more closely, act more compassionately, and recognize the value of the patient voice. No one should have to fight to be believed. Podcast: I’m Aware That I’m Rare: the phaware® podcast It took years before I finally received answers. By the time I was diagnosed with pulmonary hypertension—a rare and serious condition—my reality had already changed. What I had been feeling all along was real. The signs were there. Through this journey, I realized that so many people living with rare and chronic conditions face the same experience: delayed diagnosis, being unheard, and navigating a healthcare system that isn’t always equipped to recognize complex illnesses.

Original title: “The Diagnosis They Missed: A Journey from Dismissal to Advocacy - Rare Disease Day 2026”

platelet gene signatures detecting pulmonary artery stenosis in patients with pulmonary hypertension

Original title: “Platelet gene signatures detecting pulmonary artery stenosis in patients with pulmonary hypertension.”

reversing the irreversible a case of successful surgical repair in a late presenting aortopulmonary window with severe pulmonary hypertension

Original title: “Reversing the irreversible? A case of successful surgical repair in a late-presenting aortopulmonary window with severe pulmonary hypertension.”

impact of pulmonary veno occlusive disease on posttransplant survival in pulmonary hypertension

Original title: “Impact of Pulmonary Veno-Occlusive Disease on Posttransplant Survival in Pulmonary Hypertension.”

taussig bing heart with pulmonary hypertension in a rare adult survivor multimodality imaging insights

Original title: “Taussig-Bing heart with pulmonary hypertension in a rare adult survivor: multimodality imaging insights.”